Clinical cardiac electrophysiology

Saima Karim, DO is recognized by Continental Who's Who

Retrieved on: 
Monday, August 29, 2022

A highly trained board-certified cardiologist, Dr. Saima Karim has been practicing for six years in her field.

Key Points: 
  • A highly trained board-certified cardiologist, Dr. Saima Karim has been practicing for six years in her field.
  • Dr. Karim also provides cardiac pacemaker and defibrillator implantation in adult patients as part of her work.
  • If this occurs, the defibrillator sends an electrical shock to restore the heart rate to within a normal range.
  • On a personal note, Dr. Karim enjoys spending time with her 8-year-old son, traveling, and exercising outside of work.

Impulse Dynamics Announces First Implants of Optimizer Smart Mini

Retrieved on: 
Tuesday, May 10, 2022

MARLTON, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is announcing today the first implants of its newly launched Optimizer Smart Mini, which delivers the companys proprietary CCM therapy.

Key Points: 
  • MARLTON, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is announcing today the first implants of its newly launched Optimizer Smart Mini, which delivers the companys proprietary CCM therapy.
  • The Optimizer Smart Mini provides convenience to both providers and many of their patients who suffer from heart failure.
  • Dr. Kaplan completed his first commercial implant of the Optimizer Smart Mini on May 2, 2022.
  • The company has pioneered CCM therapy, which is delivered by the companys Optimizer Smart Mini, an FDA-approved treatment verified to improve the quality of life for certain heart failure patients.

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology -- In-ear Infrasonic Hemodynography - to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Retrieved on: 
Monday, August 2, 2021

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology -- in-ear infrasonic hemodynography (IH) - for the monitoring of cardiac arrhythmias, resulting in insights beyond those that have been possible with state-of-the-art ECG monitoring. These results were presented at the Heart Rhythm Society meeting in Boston, July 30, 2021.

Key Points: 
  • The clinical trial for recruiting atrial fibrillation (AF) patients was approved by the institutional review board of The University of South Carolina School of Medicine.
  • Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data and ECG were simultaneously recorded from 15 patients in AF and 15 in SR for 20 minutes.
  • Recruited AF patients were between the ages of 45 years and 90 years and showed a variety of arrhythmias.
  • An oral presentation titled "MindMics: In-ear Infrasonic Hemodynography For Cardiac Arrhythmia Assessment Beyond ECG"was given at the Heart Rhythm Society 2021 Annual Meeting: Bringing the World of EP (Electrophysiology) Together on July 28-31.

Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability

Retrieved on: 
Wednesday, July 28, 2021

The ECLIPSE-AF Trial launched in September 2020 to study the acute safety of Galaxy's flagship CENTAURI system, which uses Pulsed Electric Field (PEF) technology to treat cardiac arrhythmias.

Key Points: 
  • The ECLIPSE-AF Trial launched in September 2020 to study the acute safety of Galaxy's flagship CENTAURI system, which uses Pulsed Electric Field (PEF) technology to treat cardiac arrhythmias.
  • "From the moment we conceived the CENTAURI System, our mission has been to democratize PEF technology, leaving the choice of the mapping system and catheter to the electrophysiologist.
  • Galaxy Medical ( www.galaxymed.com ) is a privately held medical device company based in San Carlos, CA, that is dedicated to developing therapies to treat patients with cardiac arrhythmias.
  • Formed by ATP, a leader in life sciences venture capital, Galaxy is building a portfolio of technologies to address the needs of cardiac electrophysiologists.

BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology

Retrieved on: 
Wednesday, June 30, 2021

BioSigs non-invasive computerized technology, the PURE EP(tm) System, aims to drive procedural efficiency and efficacy in electrophysiology.

Key Points: 
  • BioSigs non-invasive computerized technology, the PURE EP(tm) System, aims to drive procedural efficiency and efficacy in electrophysiology.
  • The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.
  • Previously the Company increased the patient case goal from 1000 to at least 1500 procedures by the end of 2021, having delivered 425 procedures at the end of 2020.
  • The Company is currently conducting patient cases in nine medical centers across the country.

BioSig Technologies, Inc. Invited to Present at Wall Street Conference

Retrieved on: 
Monday, May 3, 2021

The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.\nOne in 18 Americans suffers from cardiac arrhythmia.

Key Points: 
  • The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.\nOne in 18 Americans suffers from cardiac arrhythmia.
  • Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S.
  • Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
  • Investors and security holders are urged to read these documents free of charge on the SEC\'s website at http://www.sec.gov.

Implantable Cardiac Monitor Market to Thrive on Increasing Incidence of Cardiac Arrhythmias, Technological Innovations to Present Better Treatment Opportunities for Geriatric Population with Cardiac Conditions, TMR

Retrieved on: 
Tuesday, April 6, 2021

Furthermore, the implantable cardiac monitor market is estimatedto be hindered by high treatment costs and strict guidelines regulating implantable device'sapproval.

Key Points: 
  • Furthermore, the implantable cardiac monitor market is estimatedto be hindered by high treatment costs and strict guidelines regulating implantable device'sapproval.
  • The global implantable cardiac monitor market is expected to develop due to extended ECG monitoring feature and increased technological innovations.
  • The increasing geriatric population necessitates more efficient options for treatment, which is estimated topresent opportunities for businesses in the global implantable cardiac monitor market.
  • The global implantable cardiac monitor market is expected to expand as the occurrence of cardiac arrhythmias such as bradycardia and atrial fibrillation increases.

Implantable Cardiac Monitor Market to Thrive on Increasing Incidence of Cardiac Arrhythmias, Technological Innovations to Present Better Treatment Opportunities for Geriatric Population with Cardiac Conditions, TMR

Retrieved on: 
Tuesday, April 6, 2021

Furthermore, the implantable cardiac monitor market is estimatedto be hindered by high treatment costs and strict guidelines regulating implantable device'sapproval.

Key Points: 
  • Furthermore, the implantable cardiac monitor market is estimatedto be hindered by high treatment costs and strict guidelines regulating implantable device'sapproval.
  • The global implantable cardiac monitor market is expected to develop due to extended ECG monitoring feature and increased technological innovations.
  • The increasing geriatric population necessitates more efficient options for treatment, which is estimated topresent opportunities for businesses in the global implantable cardiac monitor market.
  • The global implantable cardiac monitor market is expected to expand as the occurrence of cardiac arrhythmias such as bradycardia and atrial fibrillation increases.

Global Electrophysiology Market Could Exceed $10 Billion By 2025 As Cardiovascular Devices Demand Grows

Retrieved on: 
Friday, December 11, 2020

Electrophysiology is the biomedical field that deals with the study of electric activity in the body.

Key Points: 
  • Electrophysiology is the biomedical field that deals with the study of electric activity in the body.
  • Electrophysiology includes the study of the generation of electrical activity and the effects of that electrical activity on the body.
  • Certain factors that are driving the growth of the market are increasing prevalence of target diseases, technological advancements in the field of electrophysiology, and increasing demand for catheter ablation procedures.
  • A recent report from MarketsAndMarkets projected that the global electrophysiology market is projected to reach USD 10.6 billion by 2025 from USD 6.8 billion in 2020, growing at a CAGR of 9.1% from 2020 to 2025.

Global Electrophysiology Market Could Exceed $10 Billion By 2025 As Cardiovascular Devices Demand Grows

Retrieved on: 
Friday, December 11, 2020

Electrophysiology is the biomedical field that deals with the study of electric activity in the body.

Key Points: 
  • Electrophysiology is the biomedical field that deals with the study of electric activity in the body.
  • Electrophysiology includes the study of the generation of electrical activity and the effects of that electrical activity on the body.
  • Certain factors that are driving the growth of the market are increasing prevalence of target diseases, technological advancements in the field of electrophysiology, and increasing demand for catheter ablation procedures.
  • A recent report from MarketsAndMarkets projected that the global electrophysiology market is projected to reach USD 10.6 billion by 2025 from USD 6.8 billion in 2020, growing at a CAGR of 9.1% from 2020 to 2025.